What You Should Know:

你应该知道的：

–

–

Arine

阿琳

, the leader in AI-driven medication intelligence announced it has closed a $30M Series C funding round led by

，人工智能驱动的药物智能领域的领导者，宣布已完成由...领投的3000万美元C轮融资。

Town Hall Ventures

市政厅风险投资公司

, with participation from

，参与方包括

Kaiser Permanente Ventures

凯撒医疗创投

and other existing investors. This brings Arine’s total funding to $66M.

和其他现有投资者。这使得 Arine 的总融资额达到 6600 万美元。

– The new capital will empower the company to accelerate its mission of redefining medication management across the healthcare continuum, at a time when the industry faces unprecedented financial and regulatory pressures.

— 新的资金将使该公司能够加快其在医疗保健领域重新定义药物管理的使命，尤其是在行业面临前所未有的财务和监管压力之际。

Delivering Cost-Effective Medication Therapy

提供经济有效的药物治疗

Amid mounting cost pressures and sweeping policy changes, medications have emerged as one of the most powerful—and underleveraged—tools to improve outcomes and control costs. Arine’s AI platform is designed to address this by delivering scalable, personalized, and cost-effective medication therapy, which is essential for success in value-based care..

面对不断上升的成本压力和广泛的政策变化，药物已成为改善结果和控制成本的最有力且未被充分利用的工具之一。Arine的AI平台旨在通过提供可扩展、个性化且具有成本效益的药物治疗来解决这一问题，这对于在价值导向型医疗中的成功至关重要。

“This is a defining moment for healthcare and for Arine,” said Yoona Kim, PharmD, PhD, CEO and co-founder of Arine. “Mounting cost pressures and sweeping policy changes are forcing the industry to rethink how care is delivered. With this new capital, we’re expanding our ability to deliver meaningful impact for each patient, when the system needs it most.”.

“这是医疗保健行业和Arine的一个决定性时刻，”Arine的首席执行官兼联合创始人、药学博士Yoona Kim说道，“不断上升的成本压力和广泛的政策变化正在迫使行业重新思考如何提供医疗服务。通过这笔新资金，我们正在增强为每位患者带来有意义影响的能力，这正是系统最需要的时候。”

Proven Results/Outcomes

已证明的结果/成果

Arine’s AI platform leverages large, diverse datasets to identify the right individuals for intervention, recommend the most effective therapies, and continuously measure impact to ensure meaningful outcomes. This approach has consistently delivered significant results for its clients, including:

阿琳的AI平台利用庞大而多样化的数据集来确定适合干预的个体，推荐最有效的疗法，并持续衡量影响以确保有意义的结果。这种方法始终为其客户带来显著成果，包括：

>10% in total cost savings

总成本节省超过10%

>40% reduction in hospitalizations

住院人数减少超过40%

These outcomes have led to over 100% growth in the last year and an average contract expansion of 80% with existing clients.

这些成果使得去年的业务增长超过 100%，现有客户的平均合同扩张达到 80%。

Expansion Plans

扩展计划

With the new funding, Arine will focus on several key areas to meet the evolving needs of the industry. The company plans to:

凭借新一轮融资，Arine 将专注于几个关键领域，以满足行业不断变化的需求。公司计划：

Expand its capabilities in specialty pharmacy management, a fast-growing and costly area of healthcare.

扩大其在专业药房管理方面的能力，这是医疗保健领域中一个快速增长且成本高昂的领域。

Accelerate AI innovation to automate high-volume, low-complexity tasks, allowing providers to focus more on direct patient care.

加速 AI 创新以自动化高容量、低复杂性的任务，使供应商能够更加专注于直接的患者护理。

Continue to integrate comprehensive data to further personalize medication therapy

继续整合综合数据，以进一步个性化药物治疗。